Page 197 - rcv31n3.vp

Revista Uruguaya de Cardiología Actualización en medicamentos antidiabéticos y riesgo cardiovascular
Volumen 31 | nº 3 | Diciembre 2016 María del Pilar Serra Sansone

farction (GIPS)-III trial. Cardiovasc Drugs Ther 2012; 83. MadsbadS,Kilhovd B, LagerI,Mustajoki P, Dej-
26(5):417-26. gaard A, Scandinavian Repaglinide . Comparison
between repaglinide and glipizide in type 2 diabetes
71. Ye Y, Lin Y, Perez-Polo JR, Birnbaum Y. Oral
mellitus: a 1-year multicentre study. Diabet Med
glyburide,butnotglimepiride,blockstheinfarct-sizeli-
2001;18(5):395-401.
miting effects of pioglitazone. Cardiovasc Drugs Ther
2008; 22(6):429-36. 84. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G,
Fogari R. Comparisonbetweenrepaglinideandglime-
72. Sillars B, Davis WA, Hirsch IB, Davis TM. Sulp- piride in patients with type 2 diabetes mellitus: a
honylurea-metformin combination therapy, cardiovas- one-year,randomized, double-blind assessment of me-
cular disease and all-cause mortality: the Fremantle tabolic parameters and cardiovascularrisk factors. Clin
Diabetes Study. Diabetes Obes Metab 2010; Ther 2003;25(2):472-84.
12(9):757-65.
85. HuangY,Abdelmoneim AS,LightP,QiuW,
73. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is Simpson SH. Comparative cardiovascular safety of
the combination of sulfonylureas and metformin asso- insulin secretagogues following hospitalization for is-
ciated with an increased risk of cardiovascular disease chemic heart disease among type 2 diabetes patients: a
or all-cause mortality? a meta-analysis of observational cohort study. J Diabetes Comp 2015; 29:196–202.
studies. Diabetes Care 2008; 31(8):1672-8.
86. Miyazaki Y, Mahankali A, Matsuda M, Glass L,
74. Rosenstock J, Marx N, Kahn SE, Zinman B, Kas- Mahankali S, Ferrannini E, et al. Improved glyce-
telein JJ, Lachin JM, et al. Cardiovascular outcome mic control and enhanced insulin sensitivity in type 2
trials in type 2 diabetes and the sulphonylurea contro- diabetic subjects treated with pioglitazone. Diabetes
versy: rationale for the active-comparator CAROLINA Care 2001; 24(4):710-9.
trial. Diab Vasc Dis Res 2013; 10(4):289-301.
87. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsu-
75. Lee TM, Chou TF. Impairment of myocardial protec- da M, Mari A, DeFronzo RA. Thiazolidinediones im-
tion in type 2 diabetic patients. J Clin Endocrinol Me- prove beta-cell function in type 2 diabetic patients. Am
tab 2003; 88(2):531-7. J Physiol Endocrinol Metab 2007; 292(3):E871-83.
76. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The 88. DeFronzo RA, Tripathy D, Abdul-Ghani M, Musi
potential effects of anti-diabetic medications on myo- N, Gastaldelli A. The disposition index does not re-
cardial ischemia-reperfusioninjury. Basic Res Cardiol flectâ-cellfunctioninIGT subjects treated with piogli-
2011; 106(6):925-52. tazone.JClinEndocrinolMetab2014;99(10):3774-81.

77. Holstein A, Plaschke A, Egberts EH. Lower inci- 89. Finegood DT, McArthur MD, Kojwang D, Tho-
dence of severe hypoglycaemia in patients with type 2 mas MJ, Topp BG, Leonard T, et al. Beta-cell mass
diabetestreatedwithglimepirideversusglibenclamide. dynamics in Zucker diabetic fatty rats: Rosiglitazone
Diabetes Metab Res Rev 2001; 17(6):467-73. prevents the rise in net cell death. Diabetes 2001;
50(5):1021-9.
78. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde
L, Bloomgarden ZT, Bush MA, et al. AACE/ACE 90. Mahaffey KW, Hafley G, Dickerson S, Burns S,
comprehensive diabetes management algorithm 2015. Tourt-Uhlig S, White J, et al. Results of a reevalua-
Endocr Pract 2015; 21(4):438-47. tion of cardiovascular outcomes in the RECORD trial.
Am Heart J 2013; 166(2):240-249.e1.
79. National Institute for Health and Care Excellen-
ce. Type 2 diabetes in adults: management.London: 91. Mudaliar S, Chang AR, Henry RR. Thiazolidine-
NICE, 2016. Disponible en: http://www. diones, peripheral edema, and type 2 diabetes: inciden-
nice.org.uk/ng28. [Consulta: 20 julio 2016]. ce, pathophysiology, and clinical implications. Endocr
Pract 2003; 9(5):406-16.
80. Asociación Latinoamericana de Diabetes. Mane-
jo Farmacológico de la Diabetes tipo 2: capítulo 9. En: 92. Clarke DC, Molina-Wilkins M, Martínez S, Me-
Asociación Latinoamericana de Diabetes. Guías ALAD rovci A, Kincade JR, Solís-Herrera C, et al.
sobre el diagnóstico, control y tratamiento de la diabe- Improved left ventricular diastolic function (LVDF) fo-
tes mellitus tipo 2 con medicina basada en la eviden- llowing pioglitazone therapy is strongly related to in-
cia:edición 2013. Revista ALAD 2013. Disponible en: creased myocardial insulin sensitivity. Diabetes
http://www.bvs.hn/Honduras/UICFCM/Diabe- 2014;63(Suppl 1):A298.
tes/GUIAS_ALAD_2013.pdfConsulta:19julio2016]. 93. Erdmann E, Dormandy JA, Charbonnel B, Mas-
si-Benedetti M, Moules IK, Skene AM; PROacti-
81. Dornhorst A. Insulinotropic meglitinide analogues.
ve Investigators. The effect of pioglitazone on recu-
Lancet 2001;358(9294):1709-16.
rrent myocardial infarction in 2,445 patients with type
82. Plosker GL, Figgitt DP. Repaglinide: a pharmacoe- 2 diabetes and previous myocardial infarction: results
conomic review of its use in type 2 diabetes mellitus. from the PROactive (PROactive 05) Study. J Am Coll
Pharmacoeconomics 2004;22(6):389-411. Cardiol 2007; 49(17):1772-80.
541